Sangamo Therapeutics, Inc. (SGMO) analyst actions
Rating and price-target actions on SGMO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SGMO overview →
2 measured SGMO analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | Press release | +3.57% | -1.71% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out | Press release | +1.45% | -0.80% |
Keep exploring
More SGMO: earnings → · SEC filings → · SGMO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EIDOS THERAPEUTICS (EIDX) | 300 | +0.01% | 51% |
| Grifols, S.A. - American Depositary Shares (GRFS) | 300 | -0.13% | 39% |
| Merit Medical Systems, Inc. (MMSI) | 299 | -0.03% | 48% |
| PLx Pharma Inc. (PLXP) | 299 | -0.05% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.